Background: Mycobacterium tuberculosis (TB) infection induces systemic inflammation that could impact HIV-1 persistence.
INTRODUCTION
HIV-1 latency presents a formidable barrier to achieving viral remission. 1,2 HIV-1-infected patients can have undetectable virus levels in the peripheral blood with combination antiretroviral therapy (cART), but the virus reemerges after cART discontinuation, presumably from latently infected cells. 3 It has been difficult to accurately quantify this reservoir because latently infected cells can have defective proviruses or fully intact HIV-1 genomes that do not yield infectious virus even on maximal in vitro stimulation. [4] [5] [6] [7] [8] Although quantitative polymerase chain reaction quantifies both defective and noninducible proviruses, this method has been accepted as 1 way to estimate the latent reservoir. 9 It is generally agreed that viral remission will require a substantial decrease in either the size or the inducibility of the HIV-1 reservoir. 10 Interestingly, in vitro studies suggest that concomitant infection with other microorganisms, such as gram-negative bacteria, may influence the establishment and maintenance of HIV-1 persistence. 11, 12 Tuberculosis (TB) is the most common coinfection in HIV-1-seropositive individuals. 13 Longitudinal examinations and cross-sectional comparisons have demonstrated that active TB disease leads to higher levels of peripheral viremia presumably because HIV-1 transcription is enhanced in the presence as compared to the absence of TBmediated inflammation. [14] [15] [16] We speculated that these higher virus levels potentially impact HIV-1 latency, and this could have implications for future strategies aimed at achieving viral remission.
MATERIAL AND METHODS

Subjects
HIV-1-infected patients were recruited from a TB diagnostic study in Kampala, Uganda. 17 The diagnostic investigation enrolled individuals that had more than 2 weeks of cough and provided 4 sputum samples. For this study, TBcoinfected cases were defined as individuals with at least 1 sputum culture positive for TB and no diagnosis of extrapulmonary TB. Controls had negative results on GeneXpert MTB/RIF, sputum smear microscopy, and 2 liquid and 1 solid media cultures. Per study protocol, controls were not screened with chest radiographs, interferon gamma release assays, or tuberculin skin testing. No study participants were diagnosed with other opportunistic infections. TB-coinfected cases initiated standard 6-month anti-TB therapy immediately, and cART was started approximately 2 weeks later. Controls began cART after HIV-1 diagnosis. Blood was collected before initiating therapy, and again at a follow-up visit approximately 6 months later at which point TB-coinfected cases had completed TB therapy, and all participants had been on cART for approximately 6 months. All subjects provided written informed consent, and the institutional review boards at the different institutions approved this study.
Plasma Cytokine Analysis
Plasma levels of interleukin (IL)-6, s-CD163, and macrophage chemoattractant protein (MCP)-1 were measured using a magnetic bead-based multiplex assay (R&D Systems, Minneapolis, MN). Quantitation was performed on a Magpix (Luminex, Austin, TX) instrument equipped with xPONENT 4.2 software.
Quantitative RNA and DNA Assay Cellular DNA and RNA were isolated from the same Ficoll-Hypaque isolated peripheral blood mononuclear cell aliquot using All Prep DNA/RNA mini kit (Qiagen, Germantown, MD). Total HIV-1 DNA, ca-RNA, and number of total cells were quantified as previously described with minor modifications. 18 All samples were assessed in triplicate, a minimum of 2 independent times.
Statistical Analysis
Groups were compared using the Wilcoxon rank sum test, and frequency differences were assessed using 2-sample test of proportions. Associations were examined using the Spearman rank correlations. All P-values are based on 2-sided tests. Statistical analysis was performed with Stata (version 14).
RESULTS
TB-Coinfected Cases and Controls Had Similar Demographics
Pretreatment demographics were not significantly different among the 15 TB-coinfected cases and 16 controls (Table S1 , Supplemental Digital Content, http://links.lww. com/QAI/B200). Five TB-coinfected cases and 5 controls did not return for their 6-month visit. Of the remaining 21 patients, only 6 TB-coinfected cases and 8 controls had viral suppression, and follow-up analysis was performed for these individuals only. Four TB-coinfected cases and 3 controls had elevated plasma virus level at follow-up suggesting either nonadherence or presence of resistant virus. After viral suppression, demographics were not significantly different among the groups, except the TB-coinfected cases had higher CD4:CD8 ratio as compared to controls (P = 0.05) (Table S1 , Supplemental Digital Content, http://links.lww.com/QAI/ B200).
Individuals With TB Have Greater Inflammation
Three myeloid-cell-associated cytokines (IL-6, s-CD163, and MCP-1) were compared because TB primarily infects macrophages, 16 and these markers have been correlated with HIV-1 associated complications. [19] [20] [21] [22] Before treatment, TB-coinfected cases had higher levels of s-CD163 (P = 0.0002) (Fig. 1A ) and IL-6 (P = 0.006) (Fig.  1B) but lower quantities of MCP-1 (P = 0.04) (Fig. 1C) as compared to controls. At the follow-up visit, IL-6 levels were FIGURE 1. Inflammatory markers differ between TB-coinfected cases and controls at baseline and after TB treatment and viral suppression. s-CD163 (A), IL-6 (B), and MCP-1 (C) among TB-coinfected cases (circles) and controls (squares) at baseline (labeled B on x axis) and follow-up (labeled F on x axis). Lines connect observations at the baseline and follow-up visit after viral suppression. Bars show median, and stars denote P value less than or equal to 0.05. Pretreatment cytokine values from 1 TB-infected individual were omitted because the results were nearly 10-fold higher compared with the other participants, suggesting that the values were spurious. below the level of detection for 5 samples (1 TB-coinfected case and 4 controls), and these values were imputed to the lowest detectable level for the assay. At follow-up, TB-coinfected cases as compared to controls had higher levels of s-CD163 (P = 0.0007) (Fig. 1A) and nonstatistically higher levels of IL-6 (P = 0.13) (Fig. 1B) and MCP-1 (P = 0.14) (Fig. 1C) .
Individuals With TB Have Decreased ca-RNA per DNA Template
The level of ca-RNA per DNA template was compared between the 2 groups because this ratio has previously shown a statistical correlation with a viral outgrowth assay in cells obtained from tissues. 23 (Table S2 , Supplemental Digital Content, http://links.lww.com/QAI/ B200). In these 4 individuals' samples, virus could be amplified using a different primer/probe set (data not shown), but estimates from this other assay were not used in the analysis because absolute quantities differ among methods that use different primer/probe sets. 18 Plasma virus level, absolute CD4 + T cell counts, and other demographics remained statistically similar among TB-coinfected cases and controls after excluding these 4 individuals. TBcoinfected cases and controls had similar number of cells isolated from the baseline (P = 0.49) and follow-up (P = 0.12) sample (Table S2 , Supplemental Digital Content, http://links. lww.com/QAI/B200). This suggests that there was no difference in cell isolation efficiency between the TB-coinfected cases as compared to controls. TB-coinfected cases and controls had similar levels of total intracellular HIV-1 DNA before treatment (P = 0.61) and after viral suppression (P = 0.27) (Fig. 2A) . Before treatment, TB-coinfected cases, however, had around 3-fold lower ca-RNA per DNA template compared with the controls (P = 0.03) (Fig. 2B) . The ca-RNA per DNA quantity were especially elevated in 2 controls (2012 and 2017) because of high ca-RNA levels (Table S2 , Supplemental Digital Content, http://links.lww.com/QAI/ B200). Although these 2 controls had no obvious atypical demographics, a statistical trend persisted even when these 2 controls were excluded from the analysis (P = 0.08). At follow-up, TB-coinfected cases had a statistical trend with around 7-fold lower ca-RNA per DNA template as compared to the controls (P = 0.07) (Fig. 2B) . One control (2013) had especially elevated ca-RNA levels at follow-up (Table S2 , Supplemental Digital Content, http://links.lww.com/QAI/ B200). Excluding 2013 from the analysis eliminated the observed statistical trend in the difference in follow-up ca-RNA per DNA (P = 0.13).
Levels of ca-RNA per DNA at follow-up were negatively correlated with baseline s-CD163 (P = 0.001) (Fig. 2C ), IL-6 (P = 0.05) (Fig. 2D) but not MCP-1 (P = 0.48) (data not shown). Level of ca-RNA per DNA at follow-up was negatively correlated with baseline s-CD163 when controls (r = 20.85, P = 0.02) but not TB-coinfected cases (r = 20.2, P = 0.78) were analyzed independently. There was no significant correlation among cytokine levels measured at follow-up with the level of ca-RNA per DNA after treatment (P . 0.05 for all assessments).
DISCUSSION
In this study, we compared plasma cytokine levels and a commonly measured marker of HIV-1 expression in individuals with and without TB. Similar investigations have not been reported, although TB infection is the most prevalent coinfection and leading cause of mortality in HIV-1-infected FIGURE 2. TB disease and systemic inflammation associates with a marker of HIV-1 expression. Level of ca-HIV-1 DNA (A) and ca-HIV-1 RNA per DNA (B) among TB-coinfected cases (circles) and controls (squares) at baseline (labeled B on x axis) and follow-up (labeled F on x axis). Lines connect observations at the baseline and follow-up visit after viral suppression. Bars show median, and stars denote P value less than or equal to 0.05. Follow-up ca-RNA per DNA (y axis) correlation with s-CD163 (C) and IL-6 (D) levels (x axis) among TB-coinfected cases (circles) and controls (squares). Cytokine levels are those present at baseline, before treatment. Solid and dotted lines show the estimated linear regression with 95% confidence interval, respectively. individuals. 13 Before conducting the study, we hypothesized that TB-coinfected individuals would have higher levels of HIV-1 expression because TB-induced inflammation would increase both the number of infected cells and viral transcription in these cells. Surprisingly, we found that TB-coinfected individuals had decreased levels of ca-RNA per DNA, which has been previously correlated with amount of inducible virus from latently infected cells. 23 In aggregate, our study suggests that TB disease before cART initiation may impact the total burden of persistent inducible infectious viruses.
TB increases HIV-1 replication, presumably because of systemic inflammation. 14, 15 Indeed, individuals with pulmonary TB had higher plasma myeloid-cell-associated cytokines, IL-6, and s-CD163, but not MCP-1. Previous studies have also reported that individuals with TB have lower MCP-1 levels as compared to those without TB disease. 24, 25 After TB treatment, the TB-coinfected cases continued to have higher s-CD163 levels. This suggests that pretreatment infections potentially continue to impact HIV-1-associated outcomes after treatment because plasma cytokines, such as s-CD163, have been linked to continued morbidity after viral suppression. 19, 20, 22 Radiological imaging has also shown that individuals with TB disease continue to have ongoing inflammation up to 1 year after successful TB treatment. 26 In aggregate, the radiologic inflammation and plasma cytokinedetected inflammation suggest that TB disease has an influence beyond the acute symptomatic period. The duration of persistence and whether other inflammation-inducing infections have similar consequences remain unclear.
In contrast to expectations, we observed that TBassociated inflammation was associated with decreased ca-RNA per DNA. 23 It is possible that active TB disease decreases HIV-1 RNA expression because it promotes infected cells that have intact HIV-1 sequences to produce progeny virions as opposed to entering a latent state. Cells actively producing virus as compared to the latently infected cells have a relatively short lifespan because they are cleared by host immune responses or viral cytopathic effects. 27, 28 In this scenario, there would be decrease in the number of cells that have transcriptionally silent intact proviruses and an accumulation of cells that harbor defective sequences. It is also possible that persistent viral transcription may be decreased because TB disease generates an inflammatory state that can affect intracellular signaling through pattern recognition receptors. 29 These signals potentially promote greater level of viral repression among the infected cells through epigenetic silencing. 7, 8, 11 Changes in the cellular milieu due to coinfections present before treatment potentially explain why virologically suppressed HIV-1-infected patients often have remarkably different number of inducible viruses, noninducible intact viral sequences, and total HIV-1 DNA. 4, 6 Interestingly, a recent study demonstrated that individuals from Uganda had significantly lower frequency of latently infected cells with replication competent HIV-1 as compared to American patients. 30 Differences in the frequency of coinfections, such as TB, among Ugandans as compared to American HIV-1-infected individuals, may potentially be a biological mechanism underlying this observation.
There are a number of limitations with our study. First, each group contained a relatively small number of individuals, which was further decreased at follow-up because of poor adherence and lack of virologic suppression. Regardless, the groups were evenly matched in factors that potentially influence HIV-1 latency, such as plasma virus level. Relatively short follow-up was another limitation. It is quite possible that HIV-1 transcriptional activity may become relatively equivalent among individuals with and without TB because HIV-1 persistence markers decrease slowly over time with continued cART suppression. 31 Finally, the controls could have had latent or unrecognized TB infection given the prevalence in the studied population. Individuals with unrecognized as compared to diagnosed TB have poorer CD4 recovery, and this could a reason the TB-negative patients had lower increases in both absolute CD4 count and the CD4:CD8 ratio compared to those with TB after viral suppression. 32 It should be noted, however, that none of the controls had TB "unmasking" after HIV-1 treatment, suggesting that they did not have undiagnosed TB disease. Longitudinal sampling among larger number of individuals with TB compared to those with no TB exposure need to be conducted to fully elucidate the effect of TB on HIV-1 persistence. Understanding how TB affects HIV-1 persistence could have implications for future strategies that aim control HIV-1 replication without cART.
